Orientador: Marlus Chorilli / Resumo: O câncer de próstata (CP) é a neoplasia maligna urológica mais comum e a segunda principal causa de mortalidade de homens associada ao câncer no mundo. O tratamento é iniciado por meio de intervenções cirúrgicas que abrangem a prostatectomia radical, tratamentos radioterápicos, terapias envolvendo privação androgênica e as imunoterapias. A quimioterapia também é bastante utilizada e recentes estudos demonstraram um controle notável do crescimento do CP utilizando docetaxel (DTX). No entanto, o DTX apresenta efeitos colaterais associados à toxicidade, tanto do fármaco como da formulação, Taxotere®. Em consequência disso, o desenvolvimento de sistemas nanotecnológicos de liberação de fármacos, como lipossomas, tem sido promissor para o tratamento do CP, em virtude das múltiplas características favoráveis desses nanosistemas, como biocompatibilidade e biodegradabilidade. Uma abordagem atrativa é a modificação superficial dos lipossomas com ligantes específicos dos receptores regulados nas superfícies de células tumorais, como os receptores de transferrina, que podem ser superexpressos em células tumorais de próstata. O atual trabalho visou desenvolver, caracterizar e avaliar a citotoxicidade in vitro de lipossomas funcionalizados com transferrina para veiculação do DTX no tratamento do CP. Os lipossomas foram obtidos por meio da técnica clássica da hidratação do filme lipídico e foram constituídos pela mistura de fosfatidilcolina de soja (SPC): colesterol (Col) : DSPE-PEG (2000)... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Prostate cancer (PC) is the most common urological malignancy and the second leading cause of cancer-related mortality in men worldwide. Treatment is initiated through surgical interventions that include radical prostatectomy, radiotherapy treatments, androgen deprivation therapies and immunotherapies. Chemotherapy is also widely used and recent studies have shown remarkable control of CP growth using docetaxel (DTX). However, DTX has side effects associated with the toxicity of both the drug and the formulation Taxotere®. As a result, the development of nanotechnological drug delivery systems, such as liposomes, has been promising for the treatment of CP, due to the multiple favorable characteristics of these nanosystems, such as biocompatibility and biodegradability. An attractive approach is the superficial modification of liposomes with receptor-specific ligands regulated on tumor cell surfaces, such as transferrin receptors, which can be overexpressed in prostate tumor cells. The present work aimed to develop, characterize and evaluate the in vitro cytotoxicity of transferrinfunctionalized liposomes for DTX delivery in the treatment of CP. The liposomes were obtained by the classical technique of hydration of the lipid film and consisted of soybean phosphatidylcholine (SPC): cholesterol (Col): DSPE-PEG (2000) -Maleimide and SPC: Col: DSPE-PEG (2000) mixture. ) -Maleimide: DTX, in the molar ratios 10: 2: 0.78 and 10: 2: 0.78: 0.52, respectively. The characterizations were... (Complete abstract click electronic access below) / Mestre

Scholarly articles related to the physical and emotional effects of prostate cancer treatment and survivorship are abundant. However, few researchers have explored resiliency of prostate cancer survivors through their recovery and survivorship experience. There is a gap in the literature regarding resilience through the lived experiences of prostate cancer survivors. Counselor educators could be better prepared to teach counselors to promote the resilience needs of prostate cancer survivors. The purpose of this hermeneutic phenomenological qualitative study was to explore and describe the lived experiences of prostate cancer survivors. Coding analysis of data collected from interviews of 7 participants generated 3 major themes and 30 subthemes of experiences. Themes included experiences and feelings surrounding the cancer diagnosis, descriptions of resilience, and the personal growth the participants gained from their experiences. The results of this study give voice to their challenges and offer insight into how prostate cancer survivors find meaning while adapting constructively to adversity and resilience. A clearer understanding of these experiences may promote understanding of the prostate cancer experience for men, offer insight for promoting resilience among prostate cancer survivors, and give clues to the experiences of other populations responding to cancer.

Breast and prostate cancers are among the two most common forms of cancer. In addition to the symptoms caused by the tumor itself, there are several sequelae associated with breast and prostate cancer that can be caused by the psychological impact of the diagnosis or from cancer treatment. Many of these symptoms can persist during the survivorship phase, even after the cancer has been treated. As such, given the large clinical population affected by these diseases, there is a strong need to identify and treat the unique symptom burden that these patients experience. While diagnosis and management of breast and prostate cancer-specific mortality have markedly developed over the years, there are still gaps in managing symptoms of cancer-related morbidity. Additionally, conventional pharmacological treatments for symptom management can come with their associated side-effects. Mindfulness-based interventions are a relatively new symptom management modality that have come as a part of a wave of cognitive-based therapies for simultaneous treatment of multiple cancer-related symptoms. Given the relative infancy of this treatment modality, much of the research has focused on its efficacy and validity as a treatment option. Even with exponential interest in this field, much of the underlying physiology of mindfulness is still unknown. This will be an examination of physiological mechanisms implicated in mindfulness-based interventions as they relate to breast and prostate cancer patients.

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第18478号 / 農博第2078号 / 新制||農||1026(附属図書館) / 学位論文||H26||N4862(農学部図書室) / 31356 / 京都大学大学院農学研究科応用生命科学専攻 / (主査)教授 植田 和光, 教授 小川 順, 教授 栗原 達夫 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DGAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第18856号 / 医博第3967号 / 新制||医||1007(附属図書館) / 31807 / 京都大学大学院医学研究科医学専攻 / (主査)教授 野田 亮, 教授 小川 誠司, 教授 松田 道行 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19552号 / 医博第4059号 / 新制||医||1012(附属図書館) / 32588 / 京都大学大学院医学研究科医学専攻 / (主査)教授 山田 泰広, 教授 藤田 潤, 教授 松田 道行 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20970号 / 医博第4316号 / 新制||医||1026(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 小川 修, 教授 戸井 雅和, 教授 万代 昌紀 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21653号 / 医博第4459号 / 新制||医||1035(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 鈴木 実, 教授 富樫 かおり, 教授 森田 智視 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

No description available.